GLAS
6.3.2024 10:18:34 CET | Business Wire | Press release
Global Loan Agency Services Limited (“GLAS”) is delighted to announce it has signed an agreement for Watiga Trust and Watiga Asia (collectively, “Watiga”) to join the GLAS network.
The transaction, subject to regulatory approval in Singapore, will significantly enhance the capabilities of GLAS in the APAC region.
Watiga’s particular expertise in alternative assets and cross-border investments in Southeast Asia will be a valuable addition alongside GLAS’s market-leading offering in loan agency, capital markets, and restructuring.
Watiga
Watiga Trust is a Licensed Trust Company, regulated by MAS, and Approved Trustee for Collective Investment Schemes. Offering a range of tailored trust, fiduciary and custodian services, Watiga Trust is a member of the Singapore Institute of Banking and Finance, the Singapore Trustees Association, Singapore Venture and Private Capital Association, and the Asia Pacific Loan Market Association. Watiga Asia offers a full suite of fund, loan and company administration services and is a member of the Singapore Fund Administrators Association.
GLAS
GLAS has served the Asian market for several years, including roles in recent high-profile debt restructurings in China such as Evergrande and Sunac.
Watiga’s platform will allow GLAS to offer a broader suite of services, including those regulated by MAS, through an established team in Singapore. Additional investment will be made to expand the team’s local capabilities and ensure consistent client delivery globally, with GLAS’s existing APAC offices in Sydney, Melbourne and Brisbane providing additional operational support to Watiga.
GLAS Founders, Mia Drennan and Brian Carne, said:
“We are delighted to partner with Watiga as a highly respected, long-established business serving the Asian market. The shared ethos, client commitment and premium service delivery has been evident through our discussions, and the complementarity of service offerings will immediately add value for our combined client base.”
Watiga Founder and Managing Director, Matt Richards, commented:
“Watiga and GLAS operate with common values of excellence in client service and have deep industry expertise in their respective areas. The merger will allow us to best serve our combined client base and give our team opportunities for further professional growth. The transaction is a natural step for the business Kuan Lim and I founded in 2012 and ensures continuity for our clients. I look forward to continuing to lead the business with additional support and investment from GLAS.”
About GLAS
GLAS was established in 2011 and is the premier independent, non-creditor, conflict-free provider of loan administration and indenture trustee services. GLAS, which services more than US$360bn of assets under administration, is headquartered in London and has operations in the US, France, Germany, Spain and Australia. By integrating with Watiga, GLAS strengthens its position in Asia, with a team of over 30 experienced professionals in Singapore and a strong foundation for further investment and growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306354876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom